Key result
Prasugrel and ticagrelor showed superiority versus clopidogrel in reducing ischemic endpoints, with an increase in bleeding events but a favorable final net clinical outcome.
Why the study?
Do prasugrel and ticagrelor reduce ischemic endpoints compared to clopidogrel?
Population
Patients requiring antiplatelet therapy
Comparison
Prasugrel and ticagrelor vs Clopidogrel
Design
Review
Authors
Loading...
May support CYP2C19 testing to flag poor responders; leaves open whether routine genotyping improves outcomes.
Do prasugrel and ticagrelor reduce ischemic endpoints compared to clopidogrel?
This review highlights that while prasugrel and ticagrelor are superior to clopidogrel in reducing ischemic events at the cost of increased bleeding, clinical application must carefully weigh efficacy, safety, and economic constraints.
Morici et al. (2014) conducted a review in Coronary ischemic events and stent thrombosis. Prasugrel and ticagrelor vs. Clopidogrel was evaluated. Prasugrel and ticagrelor showed superiority versus clopidogrel in reducing ischemic endpoints, with an increase in bleeding events but a favorable final net clinical outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: